UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 355

Sortiert nach

Diagnostic exome sequencing in early‐onset Parkinson's disease confirms VPS13C as a rare cause of autosomal‐recessive Parkinson's disease

Clinical genetics, 2018-03, Vol.93 (3), p.603-612

2018

Link zum Volltext

Verfügbarkeit prüfen

NGAL, albumin and cystatin C during cisplatin therapy

Physiological research, 2020-04, Vol.69 (2), p.307-317

2020

Link zum Volltext

Verfügbarkeit prüfen

Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib

Neoplasma, 2016, Vol.63 (3), p.471

2016

Link zum Volltext

Verfügbarkeit prüfen

Impact of delayed addition of anti-EGFR monoclonal antibodies on the outcome of first-line therapy in metastatic colorectal cancer patients: A retrospective registry-based analysis

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii165

2018

Link zum Volltext

Verfügbarkeit prüfen

Regorafenib for metastatic colorectal carcinoma: A registry-based analysis

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii156-viii157

2018

Link zum Volltext

Verfügbarkeit prüfen

2615 Efficacy and tolerability of axitinib in metastatic renal cell carcinoma (mRCC): Comparison of Czech clinical registry and AXIS trial data

European journal of cancer (1990), 2015-09, Vol.51, p.S516-S516

2015

Link zum Volltext

Verfügbarkeit prüfen

Smart Institutions for Smart Cities

IOP conference series. Earth and environmental science, 2018-08, Vol.177 (1), p.12003

2018

Link zum Volltext

Verfügbarkeit prüfen

73P GENE MUTATIONS IN SQUAMOUS-CELL NSCLC: INSIGNIFICANCE OF EGFR, KRAS AND PIK3CA MUTATIONS IN PREDICTION OF EGFR-TKI TREATMENT EFFICACY

Lung cancer (Amsterdam, Netherlands), 2013-05, Vol.80, p.S33-S33

2013

Link zum Volltext

Verfügbarkeit prüfen

Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice

Neoplasma, 2013-01, Vol.60 (1), p.26

2013

Link zum Volltext

Verfügbarkeit prüfen

9093 POSTER The Role of Specific KRAS Mutation Types in Response to Treatment by EGFR Inhibitors

European journal of cancer (1990), 2011, Vol.47, p.S620-S620

2011

Link zum Volltext

Verfügbarkeit prüfen

Estimation of potential interactive effects of chemical mixtures

Toxicology letters, 2011-08, Vol.205, p.S257-S257

2011

Link zum Volltext

Verfügbarkeit prüfen

119P The study of differentially expressed genes in metachronous colorectal liver metastasis samples using RNA sequencing

Annals of oncology, 2024-06, Vol.35, p.S56-S56

2024

Link zum Volltext

Verfügbarkeit prüfen

Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC

Neoplasma, 2013, Vol.60 (4), p.425

2013

Link zum Volltext

Verfügbarkeit prüfen

9074 POSTER DNA Hypermethylation in Progressive Advanced Non Small Cell Lung Cancer

European journal of cancer (1990), 2011, Vol.47, p.S614-S614

2011

Link zum Volltext

Verfügbarkeit prüfen

Erlotinib in the treatment of advanced squamous cell NSCLC

Neoplasma, 2013-01, Vol.60 (6), p.676

2013

Link zum Volltext

Verfügbarkeit prüfen

Papillary Renal Cell Carcinoma (pRCC): Outcomes of patients receiving first-line immune-based combinations or Tyrosine Kinase Inhibitors (TKIs) from the ARON-1 study

European urology, 2024-03, Vol.85, p.S1861-S1862

2024

Link zum Volltext

Verfügbarkeit prüfen

A0839 - Papillary Renal Cell Carcinoma (pRCC): Outcomes of patients receiving first-line immune-based combinations or Tyrosine Kinase Inhibitors (TKIs) from the ARON-1 study

European urology, 2024-03, Vol.85, p.S1861-S1862

2024

Link zum Volltext

Verfügbarkeit prüfen

Natural Disasters and Individual Behaviour in Developing Countries: Risk, Trust and the Demand for Microinsurance

Fiala, Oliver

1, 2017

Link zum Volltext

Verfügbarkeit prüfen

957P - Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)

Annals of oncology, 2019-10, Vol.30, p.v387-v387

2019

Link zum Volltext

Verfügbarkeit prüfen

Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)

Annals of oncology, 2019-10, Vol.30, p.v387

2019

Link zum Volltext

Verfügbarkeit prüfen

1897P Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations

Annals of oncology, 2023-10, Vol.34, p.S1021-S1021

2023

Link zum Volltext

Verfügbarkeit prüfen

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib

Cancer management and research, 2021-01, Vol.13, p.4077-4086

2021

Link zum Volltext

Verfügbarkeit prüfen

Side Effects and Efficacy of Immunotherapy

Klinická onkologie, 2020, Vol.33 (1)

2020

Link zum Volltext

Verfügbarkeit prüfen

Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy

Anticancer research, 2013-04, Vol.33 (4), p.1705-1711

2013

Link zum Volltext

Verfügbarkeit prüfen

Sequential therapy with bevacizumab and epidermal growth factor receptor-directed agents for metastatic colorectal carcinoma: A retrospective, registry-based analysis

Annals of oncology, 2017-09, Vol.28, p.v175-v175

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 355

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(279)
Mit Volltextzugriff
(244)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Diagnostic exome sequencing in early‐onset Parkinson's disease confirms VPS13C as a rare cause of autosomal‐recessive Parkinson's disease

NGAL, albumin and cystatin C during cisplatin therapy

Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib

Impact of delayed addition of anti-EGFR monoclonal antibodies on the outcome of first-line therapy in metastatic colorectal cancer patients: A retrospective registry-based analysis

Regorafenib for metastatic colorectal carcinoma: A registry-based analysis

2615 Efficacy and tolerability of axitinib in metastatic renal cell carcinoma (mRCC): Comparison of Czech clinical registry and AXIS trial data

Smart Institutions for Smart Cities

73P GENE MUTATIONS IN SQUAMOUS-CELL NSCLC: INSIGNIFICANCE OF EGFR, KRAS AND PIK3CA MUTATIONS IN PREDICTION OF EGFR-TKI TREATMENT EFFICACY

Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice

9093 POSTER The Role of Specific KRAS Mutation Types in Response to Treatment by EGFR Inhibitors

Estimation of potential interactive effects of chemical mixtures

119P The study of differentially expressed genes in metachronous colorectal liver metastasis samples using RNA sequencing

Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC

9074 POSTER DNA Hypermethylation in Progressive Advanced Non Small Cell Lung Cancer

Erlotinib in the treatment of advanced squamous cell NSCLC

Papillary Renal Cell Carcinoma (pRCC): Outcomes of patients receiving first-line immune-based combinations or Tyrosine Kinase Inhibitors (TKIs) from the ARON-1 study

A0839 - Papillary Renal Cell Carcinoma (pRCC): Outcomes of patients receiving first-line immune-based combinations or Tyrosine Kinase Inhibitors (TKIs) from the ARON-1 study

Natural Disasters and Individual Behaviour in Developing Countries: Risk, Trust and the Demand for Microinsurance

957P - Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)

Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)

1897P Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib

Side Effects and Efficacy of Immunotherapy

Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy

Sequential therapy with bevacizumab and epidermal growth factor receptor-directed agents for metastatic colorectal carcinoma: A retrospective, registry-based analysis

Suchergebnisse filtern